5 min. Read

Cigna clarifies new non-coverage policy for PDTs. Bevel $10M. FDA GenAI comments.

Issue 350

Welcome back to E&O: a paying subscribers-only weekly newsletter focused on three areas of health tech: FDA-regulated software devices, digital health as an employee benefit, and national virtual clinics.

Exits & Outcomes Newsletter

This week's newsletter focuses on a new Medical (non?)Coverage Policy from Cigna focused on prescription digital therapeutics. But first... a few quick notes:

New York City-based Bevel, which offers an

Sign-up for the newsletter for access.

It's a good one, too.

This article is for Exits & Outcomes subscribers only. Subscribe now to get the weekly newsletter. Enter your email below to subscribe today!

Newsletters

Flo Health’s 2025 revenue, expenses, losses and more.

7.31.26

4 min. Read

Samsung’s ACCESS Model partner. More ACCESS dropouts. Trials.

7.24.26

6 min. Read

CMS proposes to gut RPM/RTM. Thyme revenue. Swing Therapeutics acquired.

7.15.26

6 min. Read

Clinical trials snapshot: OpenEvidence, Hinge, Oura, North Shore Therapeutics, and more

7.10.26

9 min. Read

Hello Heart, Form Health pricing. Headway off the ACCESS Model list

6.26.26

3 min. Read

Oura subscription revs, rings sold, hardware margin. New ACCESS Model participants

6.05.26

7 min. Read

Six years of Oura’s financials: Revenue, profits, marketing spend and more

5.22.26

4 min. Read

ACCESS Model’s first dropout? Plus: A few new participants

5.08.26

6 min. Read

Are these Utah’s next four AI experiments? Plus: More on the Utah Pharmacy Board’s questions about Doctronic

4.17.26

9 min. Read

Emails show how Doctronic’s AI pilot blindsided Utah’s Medical Board

4.10.26

13 min. Read

Cigna clarifies new non-coverage policy for PDTs. Bevel $10M. FDA GenAI comments.

Exits & Outcomes Newsletter

Sign-up for the newsletter for access.

E&O's weekly newsletter.